Short answer
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $71M (up 44.8% year over year) with net income of −$79M.
Q1 2026 key financials · XBRL
- Revenue
- $71M
- +44.8% YoY
- Net income
- −$79M
- +32.0% YoY
- Operating margin
- -113.5%
- EPS (diluted)
- −$0.19
- +47.2% YoY
Source: XBRL data from the IOVANCE BIOTHERAPEUTICS, INC. (IOVA) Q1 2026 10-Q on SEC EDGAR. USD.
IOVANCE BIOTHERAPEUTICS, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Product revenue $71.430M, up 45% YoY from $49.324M
- Amtagvi revenue $60.222M, up 38% YoY; Proleukin revenue $11.208M, up 95%
- Cost of sales $42.498M, down 1% YoY; R&D $62.487M, down 18%
- Research spending highest for lifileucel monotherapy at $14.197M; other programs down 67% to $2.566M
- Interest income $1.333M, down 59% YoY, reflecting lower average investment balances and returns
Risk Factors
- Newly heightened reimbursement risk from OBBBA provisions, with ACA Marketplace premium tax credits expiring at 2025-end
- Most material financial risk: $2.9B accumulated deficit and $319.4M cash, investments, and restricted cash at March 31, 2026
- Regulatory risk from potential FDA requirements for additional post-marketing studies requiring substantial time, effort, and money
- Operational risk from workforce reduction of approximately 19% potentially disrupting initiatives and reducing institutional expertise
- Market risk from significant competition by biotechnology and pharmaceutical companies and nonprofit institutions
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other IOVANCE BIOTHERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.